BiotechTube

Evolocumab

ApprovedWithdrawn
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease

Trial Timeline

Aug 30, 2019 → Feb 24, 2023

NCT ID
NCT03851263

About Evolocumab

Evolocumab is a approved stage product being developed by HeartFlow for Coronary Artery Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03851263. Target conditions include Coronary Artery Disease.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Artery Disease were approved

Approved (20) Terminated (1) Active (0)
✅Clopidogrel treatment groupYuhanApproved
✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
✅statins, ezetimibe + Combination therapyYuhanApproved
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
✅PrasugrelDaiichi SankyoApproved
✅Prasugrel + ClopidogrelDaiichi SankyoApproved
✅30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03851263ApprovedWithdrawn

Competing Products

20 competing products in Coronary Artery Disease

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
27
High intensity lipid loweringHeartFlowPre-clinical
20
ExenatideEli LillyPhase 3
40
Clopidogrel treatment groupYuhanApproved
50
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)YuhanPhase 3
40
statins, ezetimibe + Combination therapyYuhanApproved
50
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
43
clopidogrel + prasugrelDaiichi SankyoPhase 1
21
PrasugrelDaiichi SankyoApproved
43
ADP receptor inhibitorsDaiichi SankyoPre-clinical
26
Pactimibe, CS-505Daiichi SankyoPhase 2
35
Prasugrel + ClopidogrelDaiichi SankyoPhase 2
35
prasugrel + clopidogrelDaiichi SankyoPhase 1
29
Prasugrel + ClopidogrelDaiichi SankyoApproved
43
Triple oral lipid lowering treatmentDaiichi SankyoPhase 3
47
Placebo + PrasugrelDaiichi SankyoPhase 3
40
30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
50